Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 26, 2017

Biogen launches Phase II multiple sclerosis trial of opicinumab

Biogen has launched the Phase II AFFINITY clinical trial of its investigational candidate opicinumab in patients suffering from relapsing multiple sclerosis (MS).

Biogen has launched the Phase II AFFINITY clinical trial of its investigational candidate opicinumab in patients suffering from relapsing multiple sclerosis (MS).

Opicinumab is a human monoclonal antibody designed to target leucine rich repeat and immunoglobin-like domain-containing protein 1 (LINGO-1).

The multi-centre, randomised, double-blind, placebo-controlled Phase II trial will assess opicinumab in 240 patients who are adequately controlled with anti-inflammatory disease-modifying therapy (DMT).

AFFINITY will investigate opicinumab as an add-on therapy, and will compare to DMT alone.

The target population for the AFFINITY trial was identified during analysis in a previous Phase II trial, SYNERGY, which showed potential response for the particular patient group.

“The SYNERGY data provide intriguing evidence that opicinumab may have a treatment effect in certain patients.”

Biogen Research & Development executive vice-president Michael Ehlers said: “As part of our long-standing commitment to the MS community, Biogen remains dedicated to advancing the treatment of MS and continues to pursue next-generation research to understand the therapeutic potential of repairing damage caused by the disease.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“The SYNERGY data provide intriguing evidence that opicinumab, which has demonstrated remyelination properties in a previous Phase II study, may have a treatment effect in certain patients.”

During SYNERGY, opicinumab is reported to have demonstrated an enhanced clinical effect in participants who had the disease for shorter periods of time.

The primary endpoint of AFFINITY will be overall response score (ORS), an integrated measurement of improvement and worsening of disability over time.

Founded in 1978, Biogen develops medicines for various neurological conditions such as MS, Alzheimer’s disease, dementia, movement and neuromuscular disorders, pain, neuropsychiatry and acute neurology.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU